S. Piscitelli

发表

The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study

I. Lombardo, G. Ramaswamy, S. Piscitelli, 2015, Alzheimer's & Dementia.

Development of Resistance During Antimicrobial Therapy: A Review of Antibiotic Classes and Patient Characteristics in 173 Studies

S. Piscitelli, D. Fish, L. Danziger, 1995, Pharmacotherapy.

Effects of Fluconazole and Clarithromycin on Rifabutin and 25-O-Desacetylrifabutin Pharmacokinetics

M. Polis, H. Masur, S. Piscitelli, 2000, Antimicrobial Agents and Chemotherapy.

Drug interactions in infectious diseases

S. Piscitelli, K. Rodvold, 2000 .

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

G. Ippolito, S. Piscitelli, A. Antinori, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chapter 19 Small Molecule CCR5 and CXCR4-Based Viral Entry Inhibitors for Anti-HIV Therapy Currently in Development

S. Piscitelli, W. Kazmierski, K. Gudmundsson, 2007 .

Pharmacokinetics and Short-Term Safety of 873140, a Novel CCR5 Antagonist, in Healthy Adult Subjects

S. Piscitelli, K. Adkison, Anne Shachoy-Clark, 2005, Antimicrobial Agents and Chemotherapy.

Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines

J. Metcalf, S. Vogel, J. Kovacs, 1996, Antimicrobial agents and chemotherapy.

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects

K. Dooley, C. Flexner, S. Piscitelli, 2013, Journal of acquired immune deficiency syndromes.

The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer

S. Piscitelli, D. Rushing, K. Rodvold, 1994, Cancer.

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis.

S. Piscitelli, Ning Zhang, E. Guttman‐Yassky, 2021, The Journal of investigative dermatology.

Effect of Milk Thistle on the Pharmacokinetics of Indinavir in Healthy Volunteers

J. Falloon, S. Piscitelli, A. Burstein, 2002, Pharmacotherapy.

The effect of garlic supplements on the pharmacokinetics of saquinavir.

J. Falloon, S. Piscitelli, A. Burstein, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

S. Piscitelli, T. Fujiwara, Y. Lou, 2009, Antimicrobial Agents and Chemotherapy.

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

S. Piscitelli, Y. Lou, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

Clinical Pharmacokinetics of Metronidazole and Other Nitroimidazole Anti-Infectives

S. Piscitelli, N. Lam, L. Danziger, 1992, Clinical pharmacokinetics.

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

S. Piscitelli, W. Figg, B. Hahn, 1997, Antimicrobial agents and chemotherapy.

Immune-Based Therapies for Treatment of HIV Infection

R. Davey, S. Piscitelli, M. Saville, 1996, The Annals of pharmacotherapy.

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

R. Davey, S. Piscitelli, K. Adkison, 2005, AIDS.

Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer's disease.

T. Fullerton, T. Sunderland, S. Molchan, 1998, Journal of clinical psychopharmacology.

Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection

J. Metcalf, R. Davey, S. Vogel, 1997, Antimicrobial agents and chemotherapy.

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.

S. Piscitelli, T. Koshiba, J. Borland, 2013, British journal of clinical pharmacology.

Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food

S. Piscitelli, S. Weller, B. Wynne, 2014, Journal of acquired immune deficiency syndromes.

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

S. Piscitelli, T. Fujiwara, W. Spreen, 2013, HIV clinical trials.

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

S. Piscitelli, H. Crauwels, W. Spreen, 2013, Antimicrobial Agents and Chemotherapy.

Formulation and pharmacology of long-acting cabotegravir

S. Piscitelli, W. Spreen, S. Ford, 2015, Current opinion in HIV and AIDS.

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls

S. Piscitelli, T. Wajima, P. Patel, 2013, Clinical pharmacology in drug development.

Gabapentin does not alter single-dose lithium pharmacokinetics.

M. Frye, R. Post, T. Kimbrell, 1998, Journal of clinical psychopharmacology.

Effects of ranitidine and sucralfate on ketoconazole bioavailability

Jerome J. Schentag, T. Goss, S. Piscitelli, 1991, Antimicrobial Agents and Chemotherapy.

Safety and Efficacy of GSK2248761, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive HIV-1-Infected Subjects

S. Piscitelli, D. Mayers, E. Dumont, 2012, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer

S. Piscitelli, D. Rushing, K. Rodvold, 1993, Clinical pharmacology and therapeutics.

The Disposition of Doxorubicin on Repeated Dosing

S. Piscitelli, D. Rushing, K. Rodvold, 1993, Journal of clinical pharmacology.

The Effect of Ritonavir on the Pharmacokinetics of Meperidine and Normeperidine

S. Piscitelli, R. Bertz, Diane Rock Kress, 2000, Pharmacotherapy.

Herb-Drug Interactions and Confounding in Clinical Trials

S. Piscitelli, A. Burstein, 2002, Journal of herbal pharmacotherapy.

Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers

S. Piscitelli, A. Burstein, R. Alfaro, 2000, Clinical pharmacology and therapeutics.

the Pharmacokinetics of Dolutegravir Ritonavir-Boosted Protease Inhibitors on Effects of Etravirine Alone and with

S. Piscitelli, Y. Lou, T. Wajima, 2011 .

Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil.

S. Piscitelli, R. Guerrant, R. Dillingham, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

S. Piscitelli, B. Sadler, J. Brandt, 2015, British journal of clinical pharmacology.

Clozapine Pharmacokinetics in Children and Adolescents with Childhood-Onset Schizophrenia

J. Rapoport, R. Baldessarini, L. Jacobsen, 2003, Journal of clinical psychopharmacology.

In Vitro and Clinical Investigation of the Relationship Between CCR5 Receptor Occupancy and Anti‐HIV Activity of Aplaviroc

S. Piscitelli, C. McDanal, K. Adkison, 2008, Journal of clinical pharmacology.

The Relationship of United States' Nationalism and Textbook Coverage of Latin America

S. Piscitelli, 1986 .

A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy.

S. Piscitelli, F. Pucino, D. Boumpas, 1999, Clinical nephrology.

Fluconazole: A New Triazole Antifungal Agent

S. Piscitelli, M. Pasko, A. D. Van Slooten, 1990, DICP : the annals of pharmacotherapy.

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

R. Davey, M. Baseler, Michael A. Polis, 1996, The Journal of infectious diseases.

Antifungal Pharmacodynamics: Concentration‐Effect Relationships in Vitro and in Vivo

S. Piscitelli, T. Walsh, A. Groll, 2001, Pharmacotherapy.

Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

S. Piscitelli, J. Peter, T. Walsh, 2000, Journal of Clinical Microbiology.

Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits

S. Piscitelli, T. Walsh, I. Bekersky, 2001, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling

S. Piscitelli, T. Walsh, D. Mickiene, 2001, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.

S. Steinberg, K. Cole, S. Piscitelli, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis

S. Piscitelli, T. Walsh, A. Groll, 2002, Antimicrobial Agents and Chemotherapy.

Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

S. Piscitelli, T. Walsh, A. Groll, 2001, Antimicrobial Agents and Chemotherapy.

Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics

S. Piscitelli, M. Somerville, L. Parish, 2021, American Journal of Clinical Dermatology.

ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

K. Tashima, S. Letendre, S. Piscitelli, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of Prednisone on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

S. Piscitelli, J. Borland, Shuguang Chen, 2013, Antimicrobial Agents and Chemotherapy.

Dosage-Dependent Antifungal Efficacy of V-Echinocandin (LY303366) against Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis

A. Francesconi, S. Piscitelli, T. Walsh, 2001, Antimicrobial Agents and Chemotherapy.

Compartmental Pharmacokinetics and Tissue Drug Distribution of the Pradimicin Derivative BMS 181184 in Rabbits

S. Piscitelli, N. Giri, Tin Sein., 1998, Antimicrobial Agents and Chemotherapy.

Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

S. Piscitelli, N. Giri, Tin Sein., 1998, Antimicrobial Agents and Chemotherapy.

Pharmacometric Analysis of the Effect of Furosemide on Suramin Pharmacokinetics

S. Piscitelli, L. Whitfield, R. Lush, 1997, Pharmacotherapy.

Streptococcus milleri group: Renewed interest in an elusive pathogen

S. Piscitelli, P. Schreckenberger, L. Danziger, 1992, European Journal of Clinical Microbiology and Infectious Diseases.

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.

S. Piscitelli, N. Giri, J. Peter, 1999, The Journal of antimicrobial chemotherapy.

Atovaquone Suspension in HIV‐Infected Volunteers: Pharmacokinetics, Pharmacodynamics, and TMP‐SMX Interaction Study

R. Davey, J. Kovacs, M. Polis, 1999, Pharmacotherapy.

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

S. Piscitelli, P. Williams, H. Crauwels, 2014, Journal of acquired immune deficiency syndromes.

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

S. Piscitelli, D. Wilfret, W. Spreen, 2014, Journal of acquired immune deficiency syndromes.

Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial.

R. Dewar, J. Metcalf, R. Davey, 1996, The Journal of infectious diseases.

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.

S. Piscitelli, N. Giri, T. Walsh, 2000, The Journal of infectious diseases.

Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model.

K. Garey, S. Piscitelli, J. Cannon, 2003, Investigative ophthalmology & visual science.

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development.

S. Piscitelli, T. Walsh, A. Groll, 1998, Advances in pharmacology.

In vitro activities of metronidazole and its hydroxy metabolite against Bacteroides spp

S. Piscitelli, P. Schreckenberger, L. Danziger, 1994, Antimicrobial Agents and Chemotherapy.

Indinavir concentrations and St John's wort

J. Falloon, S. Piscitelli, A. Burstein, 2000, The Lancet.

Interactions among drugs for HIV and opportunistic infections.

S. Piscitelli, K. Gallicano, S C Piscitelli, 2001, The New England journal of medicine.

Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma

S. Piscitelli, T. Walsh, P. Pizzo, 1994, Antimicrobial Agents and Chemotherapy.

Candidal Urinary Tract Infections: A Comprehensive Review of Their Diagnosis and Management

P. Gubbins, S. Piscitelli, L. Danziger, 1993, Pharmacotherapy.

Chapter 36 – Practical Therapeutics

S. Piscitelli, Stephen C. Piscitelli, 2004 .

Drug interactions in patients infected with human immunodeficiency virus.

M. Polis, H. Masur, C. Flexner, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits

S. Piscitelli, T. Walsh, A. Groll, 2000, Antimicrobial Agents and Chemotherapy.

Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in Rabbits

S. Piscitelli, T. Walsh, R. Petraitiene, 2001, Antimicrobial Agents and Chemotherapy.

New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety.

S. Piscitelli, K. Rodvold, Stephen C. Piscitelli, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Safety and Efficacy of Multilamellar Liposomal Nystatin against Disseminated Candidiasis in Persistently Neutropenic Rabbits

S. Piscitelli, T. Walsh, J. Bacher, 1999, Antimicrobial Agents and Chemotherapy.

Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits

S. Piscitelli, T. Walsh, A. Groll, 2003, Antimicrobial Agents and Chemotherapy.

Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.

S. Piscitelli, T. Walsh, A. Groll, 1998, Klinische Padiatrie.

Comparative Efﬁcacy and Distribution of Lipid Formulations of Amphotericin B in Experimental Candida albicans Infection of the Central Nervous System

S. Piscitelli, N. Giri, A. Groll, 2022 .

Compartmental Pharmacokinetics and Tissue Distribution of Multilamellar Liposomal Nystatin in Rabbits

Andreas H. Groll, Vidmantas Petraitis, Ruta Petraitiene, 2000, Antimicrobial Agents and Chemotherapy.

Update on nosocomial pneumonia: Etiology, pathogenesis, risk factors, and diagnosis

S. Piscitelli, D. Fish, L. Danziger, 1992 .

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis

S. Chanock, S. Piscitelli, W. Figg, 1997, Antimicrobial agents and chemotherapy.

Erratum: Diarrhea and reduced levels of antiretroviral drugs: Improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil (Clinical Infectious Disease (2004) 38 (1764-1770))

S. Piscitelli, R. Guerrant, R. Dillingham, 2004 .

Guidelines for preventing opportunistic infections among HIV-infected persons - 2002

Keiji Fukuda, Mark A. Jacobson, Cynthia L. Sears, 2002 .

Clarithromycin and azithromycin: new macrolide antibiotics.

S. Piscitelli, L. Danziger, K. Rodvold, 1992, Clinical pharmacy.

Protease inhibitors for the treatment of human immunodeficiency virus infection.

S. Piscitelli, K. Struble, T. Kakuda, 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Pharmacokinetics of Dolutegravir When Administered With Mineral Supplements in Healthy Adult Subjects

S. Piscitelli, B. Wynne, N. Arya, 2014, Journal of clinical pharmacology.

Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers.

S. Piscitelli, B. Tomlinson, S. Gardner, 2013, Clinical therapeutics.

A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

Ingrid A. Beck, M. Dybul, R. Dewar, 2004, The Journal of infectious diseases.

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.

S. Vogel, J. Falloon, H. Masur, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

S. Piscitelli, M. Reese, W. Spreen, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

S. Piscitelli, P. Patel, T. Wajima, 2011, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers.

S. Piscitelli, Apurva Patel, Y. Lou, 2011, The Journal of antimicrobial chemotherapy.

Pharmacokinetic (PK) and Pharmacodynamic (PD) Relationship of S/GSK1349572, a Next Generation Integrase Inhibitor (INI), in HIV-1 Infected Patients

S. Piscitelli, T. Fujiwara, Y. Lou, 2009 .

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy

T. Merigan, W. Verbiest, J. Neaton, 2002, AIDS.

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

S. Piscitelli, S. Weller, B. Wynne, 2016, European Journal of Clinical Pharmacology.

A Concise Guide to Diagnosis

J. Goedert, V. Georgiev, S. Piscitelli, 2007 .

Drug Interactions With Antiretrovirals for HIV Infection

S. Piscitelli, K. Struble, S. M. Robertson, 2011 .

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

S. Piscitelli, T. Fujiwara, T. Hawkins, 2011, AIDS.

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.

R. Dewar, J. Metcalf, R. Davey, 1999, The Journal of infectious diseases.

Pharmacokinetic Studies with Recombinant Cytokines

S. Piscitelli, W. Figg, W. Petros, 1997, Clinical pharmacokinetics.

Therapeutic Monitoring and Pharmacist Intervention in a Hansen's Disease Clinic

J. D. Robinson, D. West, S. Piscitelli, 1993, The Annals of pharmacotherapy.

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.

J. Metcalf, R. Davey, J. Kovacs, 1997, The Journal of infectious diseases.

Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.

M. Christian, M. Kelley, S. Piscitelli, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relative Bioavailability of a Paediatric Granule Formulation of the HIV Integrase Inhibitor Dolutegravir in Healthy Adult Subjects

S. Piscitelli, T. Wajima, P. Patel, 2014, Antiviral therapy.

Steady-State Pharmacokinetics of Cefoperazone and Sulbactam in Patients with Acute Appendicitis

S. Piscitelli, L. Danziger, K. Rodvold, 1994, The Annals of pharmacotherapy.

One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial.

B. Strober, M. Lebwohl, S. Piscitelli, 2022, Journal of the American Academy of Dermatology.

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

B. Strober, M. Lebwohl, S. Piscitelli, 2021, The New England journal of medicine.

Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients.

S. Piscitelli, K. Struble, 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine

D. Samid, S. Piscitelli, D. Headlee, 1995, Journal of clinical pharmacology.

Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients

J. Kovacs, S. Piscitelli, A. Burstein, 2004, Antimicrobial Agents and Chemotherapy.

Concentration-targeted therapy and the future of HIV management.

C. Flexner, S. Piscitelli, 2002, AIDS.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol

S. Piscitelli, T. Wajima, J. Borland, 2015, The Annals of pharmacotherapy.

The role of therapeutic drug monitoring in the management of HIV-infected patients

S. Piscitelli, 2002, Current infectious disease reports.

Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio: call for consensus.

R. Haubrich, C. Flexner, S. Piscitelli, 2001, Journal of acquired immune deficiency syndromes.

USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus: A Summary

David R. Holtgrave, K. Sepkowitz, S. Dowell, 1996, Annals of Internal Medicine.

An overview of the 1999 US Public Health Service/Infectious Diseases Society of America guidelines for preventing opportunistic infections in human immunodeficiency virus-infected persons.

David R. Holtgrave, K. Holmes, K. Freedberg, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir

S. Piscitelli, J. Rubio, D. Wilfret, 2014, European Journal of Clinical Pharmacology.

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

S. Piscitelli, S. Castellino, I. Goljer, 2013, Antimicrobial Agents and Chemotherapy.

An update on drug interactions with zidovudine.

M. Polis, S. Piscitelli, 1998, AIDS patient care and STDs.

Tentacle regeneration in Hydra: a quantitative methodological approach.

S. Piscitelli, G. Nolfe, P. Pierobon, 1987, Journal of biomedical engineering.

Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.

J. Rapoport, J. Frazier, S. Piscitelli, 1994, The Journal of clinical psychiatry.

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

S. Piscitelli, S. Weller, B. Wynne, 2013, European Journal of Clinical Pharmacology.

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744

S. Piscitelli, W. Spreen, E. Dumont, 2012, Antimicrobial Agents and Chemotherapy.

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

S. Piscitelli, Y. Lou, T. Wajima, 2011, British journal of clinical pharmacology.

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

S. Piscitelli, Y. Lou, P. Patel, 2011, Journal of clinical pharmacology.

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects

S. Piscitelli, Y. Lou, T. Wajima, 2010, Journal of acquired immune deficiency syndromes.

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.

S. Piscitelli, J. Rubio, A. Yeo, 2014, Pharmacogenomics.

Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program

J. Silverberg, S. Piscitelli, R. Bissonnette, 2021, SKIN The Journal of Cutaneous Medicine.

Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis

S. Piscitelli, M. Somerville, L. Parish, 2020 .

Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

B. Strober, M. Lebwohl, A. Armstrong, 2020 .

Update on preventing vertical transmission of HIV type 1.

S. Piscitelli, A. Pau, F. Chen, 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.

S. Piscitelli, K. Adkison, Anne Shachoy-Clark, 2006, British Journal of Clinical Pharmacology.

A Multiple Drug Interaction Study of Stavudine with Agents for Opportunistic Infections in Human Immunodeficiency Virus-Infected Patients

R. Davey, J. Kovacs, M. Polis, 1999, Antimicrobial Agents and Chemotherapy.

Alteration in Indinavir Clearance During Interleukin‐2 Infusions in Patients Infected with the Human Immunodeficiency Virus

J. Metcalf, S. Vogel, S. Piscitelli, 1998, Pharmacotherapy.

High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies.

S. Piscitelli, T. Walsh, A. Groll, 1999, Journal of chromatography. B, Biomedical sciences and applications.

Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.

S. Piscitelli, T. Wajima, P. Geoffroy, 2013, Drug and alcohol dependence.

A Risk-Benefit Assessment of Interleukin-2 as an Adjunct to Antiviral Therapy in HIV Infection

S. Piscitelli, N. Bhat, A. Pau, 2000, Drug safety.

The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer

S. Piscitelli, D. Rushing, K. Rodvold, 2006 .

Thalidomide in diseases associated with human immunodeficiency virus infection.

S. Piscitelli, J. R. Minor, 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Drug-Cytokine Interactions

S. Piscitelli, W. Reiss, 1998, BioDrugs.

Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

S. Piscitelli, D. Mayers, Scott White, 2012, British Journal of Clinical Pharmacology.

Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen

C. Yoder, R. Dewar, J. Metcalf, 2003, AIDS.

Recent Progress in the Discovery of New CCR5 and CXCR4 Chemokine Receptor Antagonists as Inhibitors of HIV-1 Entry. Part 2*

Stephen Jenkinson, S. Piscitelli, W. Kazmierski, 2005 .

Pharmacokinetics and Pharmacodynamics of Subcutaneous Interleukin‐2 in HIV‐Infected Patients

J. Metcalf, R. Davey, M. Baseler, 1996, Pharmacotherapy.

Pharmacokinetic modeling of recombinant interleukin‐2 in patients with human immunodeficiency virus infection

J. Metcalf, R. Davey, M. Baseler, 1998, Clinical pharmacology and therapeutics.